Allergy Research Group, Inc. Reports Increased Sales and Net Income for Third Quarter

ALAMEDA------November 8, 2006-----Allergy Research Group, Inc. (OTCBB:ALRG) announced financial results for the third quarter ending September 30, 2006.

ALRG recorded total revenue of $4,091,460 for the quarter, up 7% from 2005. The increase of $256,446 is primarily due to increased sales to distributors and retail accounts.

Cost of sales increased $183,402 to $2,529,300 for the quarter ended September 30, 2006, compared to $2,345,898 for the quarter ended September 30, 2005. The increase in cost of sales is due to the increase in sales compounded by increased freight costs. Gross profit margins remained stable at 38%.

During the quarter ended September 30, 2006, the Company recorded net earnings of $291,434 as compared to net earnings of $244,274 for the same period in 2005. Net income increased primarily because of increased sales.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Modest Increased Sales for Second Quarter

ALAMEDA---------August 10, 2006--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the quarter ending June 30, 2006.

ALRG announces revenues of $3,996,496 for the quarter ended June 30, 2006, an increase of 0.4% compared to $3,981,676 for the same period last year. The modest increase is due primarily to increased sales to distributors, while sales to professional accounts and retail customers have decreased.

“We anticipate that, with our current marketing efforts and introduction of new products, we will see sales increase over the remainder of the year,” said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D.

Cost of sales increased $87,403 to $2,467,028 for the quarter ended June 30, 2006, compared to $2,379,625 for the quarter ended June 30, 2005.  The increase corresponds to the increase in sales compounded by increased cost of materials.  Gross profit margins were approximately 38% for 2006 and 41% for 2005. In addition to the increased cost of materials, there is a downward pressure on margins due to increased sales to distributors and decreased sales to retail customers. ALRG has responded to the decrease in margins by raising prices on several items in January 2006.

Net earnings after tax for June 30, 2006 and 2005 were $257,856 and $324,710, respectively.  The decrease is due primarily to the decrease in profit margins and increased operating expenses.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections.  Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise.  Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability and cost of raw materials, pricing, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.

(top)

Allergy Research Group, Inc. Announces New National Accounts Manager

ALAMEDA---------June 5, 2006--------Allergy Research Group, Inc. (ALRG) today announced the appointment of Reesa Sokoloff to the position of National Accounts Manager.

"We are pleased to have Reesa onboard to fill this important position. This is the first step to redouble our sales and marketing efforts and to improve our service to our Distributors, Retailer and Professional Customers," said President, Fred Salomon.

Reesa comes to Allergy Research Group with over 11 years experience as a clinical dietitian and nutritional medical consultant. She has run her own private practice, co-authored a book on an all natural sweeteners and lectured to physicians, health care professionals and corporations on topics related to wellness and nutrition. She was also the East Coast Sales Rep for Allergy Research Group from 1998-1999.

Additionally, Reesa has extensive sales and marketing experience and has been the lead consultant for the successful launch of several neutraceutical products for prestigious companies in our industry. Most recently, as Co-Founder and Director of Sales for The Sweet Life, Reesa was responsible for introducing Xylitol, an all natural sweetener, to retailers in the U.S., UK, Canada and Australia.

Reesa received her Master of Science in Clinical Nutrition from New York University and her Bachelor of Science in Food and Business from the State University of New York Oneonta.

"We have an exceptionally talented group at ARG and Reesa will fit in perfectly," said Salomon.

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections.  Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise.  Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.

(top)

Allergy Research Group, Inc. Reports Increased Sales for First Quarter

ALAMEDA---------May 15, 2006--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the quarter ending March 31, 2006.

ALRG announces revenues of $4,265,527 for the quarter ended March 31, 2006, an increase of 4% compared to $4,111,173 for the same period last year. The increase in sales is due to the introduction of new products and increased support from our distributors.

“I am encouraged by our continued growth and the positive affect our products bring to our customer base.  We are continuing with the recruitment process to expand our sales force and look forward to the benefit derived,” said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D.

Cost of sales increased $207,125 to $2,630,510 for the quarter ended March 31, 2006, compared to $2,423,385 for the quarter ended March 31, 2005.  The increase corresponds to the increase in sales compounded by increased cost of materials.  Gross profit margins were approximately 38% for 2006 and 41% for 2005. In addition to the increased cost of materials, there is a downward pressure on margins due to increased sales to distributors and decreased sales to retail customers. We responded to the decrease in margins by raising prices on several items in January 2006.

Net income after tax for March 31, 2006 and 2005 was $325,683 and $319,533, respectively.  The increase is due primarily to increased sales and decreased operating expenses offset by decreased margins and a larger provision for income tax expense.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation.  Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections.  Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict.  These statements are subject to risks and uncertainties and therefore actual results may differ materially.  The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise.  Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.

(top)

Allergy Research Group, Inc. Reports Increased Revenues For 2005

ALAMEDA------April 6, 2006------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the year ending December 31, 2005.

ALRG announces revenues of $15,911,221 for the year ended December 31, 2005, an increase of 5% compared to $15,136,592 for the year ending December 31, 2004. The increase in sales is due to the introduction of new products and effective marketing efforts.

“We plan to continue our efforts to increase sales by expanding into targeted regions through foreign distributors and by expanding our existing sales force,” said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D.

Cost of sales increased $978,215 to $9,645,293 for the year ended December 31, 2005, compared to $8,667,078 for the year ended December 31, 2004.  The increase corresponds to the increase in sales compounded by increased cost of materials.  Gross profit margins were approximately 39% for 2005 and 43% for 2004. In addition to the increased cost of materials, there is a slight downward pressure on margins due to the mix between sales to retail customers and distributors. We responded to the decrease in margins by raising prices on several items in January 2006.

Net income after tax for December 31, 2005 and 2004 was $1,208,869 and $1,282,736, respectively.  The decrease is due primarily to decreased margins, increased operating expenses offset by a smaller provision for income tax expense.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.

(top)